Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bone Biologics Corp. (BBLG : NSDQ)

• Company Description    Bone Biologics Corp. is a developer of orthobiologic products for spine fusion markets. Bone Biologics Corp. is based in BURLINGTON, Mass. Number of Employees: 2

• Price / Volume Information    Yesterday's Closing Price: $1.37 Daily Weekly Monthly 20 Day Moving Average: 37,272 shares Shares Outstanding: 10.35 (millions) Market Capitalization: $14.18 (millions) Beta: 52 Week High: $7.12 52 Week Low: $1.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -39.65% -33.87% 12 Week -32.18% -26.41% Year To Date -61.08% -53.72%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 BURLINGTON WOODS DRIVE SUITE 100 - BURLINGTON,MA 01803 USA ph: 781-552-4452 fax: - kgolodetz@lhai.com http://www.bonebiologics.com

• General Corporate Information    Officers Jeffrey Frelick - Chief Executive Officer and President Don Hankey - Chairman of the Board of Directors Deina H. Walsh - Chief Financial Officer Bruce Stroever - Director Erick Lucera - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 098070303 SIC: 3842 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 10.35 Most Recent Split Date: (:1) Beta: Market Capitalization: $14.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.83 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.35 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -16.67% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - 110.98 12/31/21 - 66.81 09/30/21 - - Quick Ratio 03/31/22 - - 12/31/21 - 66.81 09/30/21 - - Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.58 12/31/21 - 0.64 09/30/21 - - Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - - Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - -

Powered by Zacks Investment Research ©